The EU Biotech Act is a legislative initiative aimed at simplifying biotech regulation, boosting innovation and investment, and strengthening Europe’s competitiveness and biotech ecosystem, which we…
BackgroundWe previously set out the background and genesis of the proposed regulatory provisions of the "Proposal for a Directive of the European Parliament and of the Council on the Union Code…
In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions (PTE): Otsuka…
Preliminary injunctions (“PIs”) matter in life sciences patent cases. As often as not, the party which prevails at this stage of the litigation will have the upper hand in settlement negotiations. …
The Russian Intellectual Property Court (IPC) recently revoked an extension (SPC) of Pfizer's Eurasian patent No. 012666 relating to the composition of tofacitinib in relation to the Russian…
On 1 September 2025, Michael Tappin KC sitting as a Deputy Judge of the High Court handed down a judgment in favour of Bayer’s application to strike out Sandoz’s claim for an account of profits under…
Readers will likely be aware of the cross-jurisdictional litigation considering infringement by Samsung Bioepis / Amgen’s biosimilar eculizumab products of Alexion’s patent, EP 3 167 888 B1 (“EP 888”…
The final week of July usually produces a flurry, and sometimes an avalanche, of decisions from the English Courts as Judges attempt to clear their desks before the holiday period. This year was no…
Tempus fugit. It’s hard to believe that the UPC opened for business over two years ago and, after a relatively slow start, is now flourishing. It would be fair to say that, with certain notable…
